Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia
Assessment of the Safety of the VascuActive™ Device and Its Preliminary Efficacy on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With Peripheral Vascular Disease and Limb Ischemia
1 other identifier
interventional
15
1 country
1
Brief Summary
The purpose of this study is to assess the safety and the immediate effect of the VascuActive device on patients with peripheral vascular disease and limb ischemia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2009
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2009
CompletedFirst Submitted
Initial submission to the registry
November 11, 2009
CompletedFirst Posted
Study publicly available on registry
November 17, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2010
CompletedMay 21, 2010
May 1, 2010
5 months
November 11, 2009
May 20, 2010
Conditions
Outcome Measures
Primary Outcomes (1)
Pain-free and Maximal walking distance
1 hour
Secondary Outcomes (3)
Skin temperature
1 hour
Skin blood flow
1 hour
Transcutaneous partial pressure of O2 and CO2
1 hour
Interventions
Eligibility Criteria
You may qualify if:
- Leg Ischemia, Fontaine grade IIa and IIb, i.e.: pain free walking distance in the range of 50 - 100 meters.
- Absent pulses in the two foot arteries (Anterior Tibial a., Posterior Tibial a.)
- ABI \< 0.7 by Doppler, in at least one of the two foot arteries
You may not qualify if:
- Absent femoral pulses
- Venous insufficiency by Duplex
- Pregnancy
- Infectious disease
- Malignant disease
- Severe cardiac disease, e.g., CHF grade 3 or higher
- Acute MI within last 3 months
- CABG within last 3 months
- Other severe systemic disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- VascuActive LTDlead
Study Sites (1)
Asaf Harofe Medical Center
Zrifin, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 11, 2009
First Posted
November 17, 2009
Study Start
November 1, 2009
Primary Completion
April 1, 2010
Study Completion
April 1, 2010
Last Updated
May 21, 2010
Record last verified: 2010-05